Table 2.
Influence of Treatment with Gallic Acid (GA) and Gallic Acid Nanocomposite (GA-NC) on Serum β-cell Leukemia/lymphoma 2 (Bcl-2), Pro-caspase 3 and Lipocalin-2 (LCN-2) Levels in Hepatocellular Carcinoma (HCC) Afflicted Rats
| Groups | AFP ng/ml | ENG ng/ml | HSP-70 ng/ L |
|---|---|---|---|
| Negative control | 38.0 6± 0.50 | 3.11 ± 0.17 | 31.88 ± 1.341 |
| HCC | 58.88 ± 1.863a | 12.36 ± 0.82a | 66.24 ± 1.383a |
| (54.7%) | (297.4%) | (107.8%) | |
| HCC + GA | 41.19 ± 0.83b | 4.16 ± 0.14b | 43.56 ± 0.8426b |
| (-30.04%) | (-66.3%) | (-34.2%) | |
| HCC + GA-NC | 39.10 ± 0.57b | 3.50 ± 0.14b | 39.11 ± 1.141b |
| (-33.6%) | (-71.7%) | (-40.95%) |
a
Significant difference versus negative control group,
b
Significant difference versus HCC group